Bill Martin, PhD
Bill Martin is the chief scientific officer and head of research and development at BlackThorn Therapeutics, a company focused on creating novel targeted medicines for neurodevelopmental disorders. Prior to joining BlackThorn, Martin worked at Theravance Biopharma, where his responsibilities ranged from drug discovery and development, to research portfolio planning and business development. He is the chair of SfN’s Government and Public Affairs Committee. Martin graduated from Swarthmore College and earned his PhD from Brown University. He conducted postdoctoral research at the Keck Center for Integrative Neuroscience at the University of California, San Francisco.
Brenda Bloodgood, PhD
Brenda Bloodgood is an assistant professor of neurobiology in the Division of Biological Sciences at UC San Diego. Bloodgood’s main research interests lie in how neuronal computations change in response to environmental interactions. She received her BS in animal physiology and neuroscience from UC San Diego and her PhD in neurobiology from Harvard Medical School. She completed her postdoctoral training at Harvard Medical School.
Lyle B. Dennis is a partner in Cavarocchi-Ruscio-Dennis Associates, a government relations firm in Washington, DC. He serves as a member of the steering committee of the Ad Hoc Group for Medical Research, the leading advocacy group for NIH. Dennis frequently lectures about public policy issues at universities and in front of corporate and not-for-profit organizations.